MAPT and Alzheimer disease: In addition to gliosis reduction, we reported Aβ plaques and p‐Tau diminution in EOAD and late‐onset Alzheimer disease (LOAD) mice models after sEHi treatment, pinpointing the ability of sEHi to modulate the two major AD hallmarks.23